{"id":558058,"date":"2026-07-19T21:54:15","date_gmt":"2026-07-19T21:54:15","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/558058\/"},"modified":"2026-07-19T21:54:15","modified_gmt":"2026-07-19T21:54:15","slug":"what-is-the-true-clinical-impact-of-subclinical-ctrcd-cardio-oncology-bulletin","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/558058\/","title":{"rendered":"What is the True Clinical Impact of Subclinical CTRCD &#8211; Cardio-Oncology Bulletin"},"content":{"rendered":"<p>Cardio-Oncology Bulletin shared on <a href=\"https:\/\/www.linkedin.com\/posts\/cardiooncology-iranianabrcardioabroncologyabrassiciation-ugcPost-7484254328078282753-OEgw\/?utm_source=share&amp;utm_medium=member_desktop&amp;rcm=ACoAAGiH2osByVMZ_68jrekNzjhlyuiI9f_TXCQ\" target=\"_blank\" rel=\"noopener nofollow\">LinkedIn<\/a>:<\/p>\n<p>\u201cCardio-Oncology Bulletin of Iranian Cardio-Oncology Association \u2013 Issue #5<\/p>\n<p>A monthly evidence update at the intersection of cardiology and oncology<br \/>Featured Study: Moreno-Arciniegas et al.<br \/>JACC: CardioOncology, 2026<\/p>\n<p>When intensive surveillance detects more abnormalities, does it necessarily deliver more clinically meaningful information?<\/p>\n<p>Cardiovascular surveillance during anthracycline therapy is intended to identify cardiac injury before it progresses to clinically significant dysfunction. However, most surveillance recommendations are informed by expert consensus and are frequently extended to patients at low-to-intermediate baseline cardiovascular risk \u2013 precisely the group in whom the balance between early detection, clinical relevance, and resource use remains uncertain.<\/p>\n<p>The prospective, single-center MATRIX study evaluated cancer treatment\u2013naive adults with newly diagnosed lymphoma receiving anthracycline-based chemotherapy, using intensive serial multimodality surveillance over 10 months.<\/p>\n<p>What did the study find?<br \/>ESC-defined CTRCD was identified in 48% of patients: 41% mild and 7% moderate.<br \/>When biomarker criteria were excluded, the proportion classified as having CTRCD decreased to 30%: 25% mild and 5% moderate.<br \/>Most detected abnormalities were mild and frequently intermittent.<br \/>No major cardiovascular events were observed during the reported short-term follow-up.<br \/>\nWhy does this matter?<br \/>The study does not show that surveillance is unnecessary. Instead, it demonstrates how strongly CTRCD rates depend on the diagnostic components used \u2013 particularly cardiac biomarkers \u2013 and raises an important question: which subclinical abnormalities meaningfully change treatment, prognosis, or patient outcomes?<br \/>A high detection rate should therefore not automatically be interpreted as a high clinical yield.<br \/>\nTake-home message<br \/>In low-to-intermediate-risk patients receiving anthracyclines, intensive surveillance may identify frequent mild or transient abnormalities whose short-term clinical significance remains uncertain. Future studies should determine which findings warrant intervention and whether more individualized, risk-adapted surveillance can preserve safety while reducing unnecessary testing.<\/p>\n<p><a href=\"https:\/\/www.linkedin.com\/safety\/go\/?url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS2666087326001249&amp;urlhash=eTEy&amp;mt=2pvP8ffhG2Og4UtCK4AsRJSHENjmV51n2uAJCZxAHY5ZNGjyHrarfiznerLBLMA98hml95l7Tcyi6DQD5w7oM9J9B1jlqSioyZsbEkBH7mobh_awLSsvz3Aoq14VAtnMVfWrqOBZ1MV9gr-fYTIJCbkqFQ0lecKilA&amp;isSdui=true&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BvsB%2FVWUzSxq8AjPyXQYbAQ%3D%3D\" target=\"_blank\" rel=\"noopener nofollow\">Read the full article<\/a>\u201d<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-546175\" src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/07\/1784385277845.webp\" alt=\"Cardio-Oncology Bulletin\" width=\"373\" height=\"279\" title=\"What is the True Clinical Impact of Subclinical CTRCD - Cardio-Oncology Bulletin 2\"  \/><\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>Other articles about <a href=\"https:\/\/oncodaily.com\/tag\/cardio-oncology-bulletin\" rel=\"nofollow noopener\" target=\"_blank\">Cardio-Oncology Bulletin<\/a> on OncoDaily.<\/p>\n","protected":false},"excerpt":{"rendered":"Cardio-Oncology Bulletin shared on LinkedIn: \u201cCardio-Oncology Bulletin of Iranian Cardio-Oncology Association \u2013 Issue #5 A monthly evidence update&hellip;\n","protected":false},"author":2,"featured_media":558059,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-558058","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/558058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=558058"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/558058\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/558059"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=558058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=558058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=558058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}